Independent peptide intelligence: 2,700+ vendors, 8,600+ price changes tracked, 1,200+ cited studies. Ranked by data, never revenue. No paywall, no affiliates.
Visit ➡️
Joined November 2022
- Tweets1.6K
- Following18
- Followers3.9K
- Likes5.2K
Pinned Tweet
peptidebase.io what's actually in it:
→ 189 research vendors
→ 1,012 COAs on file, 807 published, 238 matched against the issuing lab's own records. 13 labs, 57 compounds.
→ 2,700+ providers — telehealth, clinics, 503A/503B pharmacies, filterable by country / state, type, and compound carried.
→ 118 compounds, each graded by how much published research exists, with current regulatory status.
→ 1,279 vendor prices across 44 compounds, re-captured weekly. Median $/mg with the full range. (Being upgraded)
→ FDA vote tracker.
→ And more
No account needed. No payment.
0 paid placements no vendor, provider or affiliate has ever paid us a dollar.
More coming.
💳 Peptide ads next?
LegitScript, the certifier ad and payment platforms rely on, told clients how HHS's 6-peptide policy affects certification, per a notice shared by @jefftangx:
• Retatrutide and cagrilintide "remain a barrier"
• Platforms still decide independently
🇮🇳 India cleared another generic semaglutide pill.
Sun Pharma won approval for oral semaglutide (3, 7, 14 mg) for type 2 diabetes, per ET Pharma.
• Equivalent to Novo's Rybelsus
• Follows Torrent and Dr. Reddy's
• Launch needs court OK amid Novo patent fight, per Mint
💉 $149 a month.
That's Superpower's price for prescription BPC-157 and TB-500. MOTS-c: $199.
• Pre-orders open now
• Target ship: late Nov, pending pharmacy confirmation
• Rx + blood test required
Not FDA-approved. Offered under HHS's interim policy.
A new era has begun.
ANNOUNCING: Superpower Peptides.
Prescription peptide care, connected with your blood testing.
For the first time, Superpower brings prescribed peptide treatments together with membership, beginning with BPC-157, TB-500 and MOTS-c.
Each one comes with:
- Treatment prescribed by licensed providers
- Comprehensive blood testing
- Clinical evaluation
- Third-party testing
- Regular check-ins and lab monitoring
- Active ingredients from FDA-registered facilities
- Prescriptions filled by US-licensed pharmacies
Because access to peptides has often outpaced guidance.
Your health history, goals and baseline bloodwork are reviewed by a licensed clinician, who can then monitor your health throughout treatment.
We’ve been preparing for this moment.
Your can start your blood test today, and at the end of November, we’re bringing peptides to you.
Pre-orders are open now:
superpower.com/peptides
🚨Believed to be Australia's first peptide-linked death.
A coroner found actor Richard Norton's death, at 75, was "triggered by" CJC-1295 and ipamorelin.
Prescribed by a doctor. Made by a licensed compounding pharmacy.
He took more than prescribed. The coroner wants a TGA review .
Australian actor dies after injecting peptides - in what is believed to be the nation's first death linked to the unapproved products trib.al/L76XFMN
🚨FDA's peptide compounding policy has cleared White House review.
• Sent to OIRA Oct 14
• Review concluded Oct 27, per reginfo.gov
• Result: "Consistent with Change," meaning the draft was edited during review
• Met with reviewers: AAPM, Hims & Hers, Alliance for Pharmacy Compounding, CSPI
How we got here:
• 2023: FDA restricted BPC-157 and other peptides over safety concerns
• July 2026: FDA advisers backed 6 of 7 peptides for compounding; FDA staff opposed all 7
• AP, citing two unnamed sources: the policy would temporarily allow some, including BPC-157
FDA can publish it any day.
Final text and peptide list: unknown.
Which peptides make the cut?
$HIMS
🚨 BREAKING: FDA PEPTIDE POLICY PASSES WHITE HOUSE REVIEW
NOW MARKED "CONSISTENT WITH CHANGE" ON REGINFO DATABASE
- Review officially concluded Oct. 27
- FDA can now move toward issuing its interim peptide compounding policy
- Likely to expand access to certain peptides (eg, BPC-157, TB-500) under regulatory safeguards
- Awaiting official FDA publication, could happen any time
Peptide Base retweeted
🚨FDA's peptide compounding policy has cleared White House review.
• Sent to OIRA Oct 14
• Review concluded Oct 27, per reginfo.gov
• Result: "Consistent with Change," meaning the draft was edited during review
• Met with reviewers: AAPM, Hims & Hers, Alliance for Pharmacy Compounding, CSPI
How we got here:
• 2023: FDA restricted BPC-157 and other peptides over safety concerns
• July 2026: FDA advisers backed 6 of 7 peptides for compounding; FDA staff opposed all 7
• AP, citing two unnamed sources: the policy would temporarily allow some, including BPC-157
FDA can publish it any day.
Final text and peptide list: unknown.
Which peptides make the cut?
$HIMS
🚨 BREAKING: FDA PEPTIDE POLICY PASSES WHITE HOUSE REVIEW
NOW MARKED "CONSISTENT WITH CHANGE" ON REGINFO DATABASE
- Review officially concluded Oct. 27
- FDA can now move toward issuing its interim peptide compounding policy
- Likely to expand access to certain peptides (eg, BPC-157, TB-500) under regulatory safeguards
- Awaiting official FDA publication, could happen any time
Peptide Base retweeted
Retatrutide just beat Ozempic head-to-head.
Lilly's Phase 3 TRANSCEND-T2D-2:
1,298 adults with type 2 diabetes, 80 weeks, vs Ozempic's top 2 mg dose.
• Weight: -20.9% vs -9.4%
• A1C: -2.2% vs -1.8%
• Quit over side effects: 7.9% vs 2.7%
• Skin-sensation side effect (dysesthesia): 6.5% vs 2.7%
What's next:
• TRIUMPH-5 vs tirzepatide: results est. Nov 2026
• FDA filing planned Q1 2027
Topline company data, not yet peer-reviewed.
Retatrutide is not approved anywhere.
Can tirzepatide hold its ground?
🚨Update: the policy is out.
HHS says it won't take enforcement action against 503A pharmacies compounding 6 peptides while FDA works on a formal rule.
Allowed forms:
• BPC-157: injection, oral, topical
• TB-500: injection
• MOTS-c: injection
• Epitalon: injection, intermittent courses
• Semax: nasal
• KPV: oral, topical
Conditions:
• Patient-specific prescription
• Ingredients from FDA-registered makers, with lab certificates
• Single ingredient only
• Serious side effects reported to FDA
Still not FDA-approved. HHS says it can revisit if safety issues arise.
Formally publishes Oct 30. Public comments are open for 2 weeks.
Which peptide gets added next?
🚨FDA's peptide compounding policy has cleared White House review.
• Sent to OIRA Oct 14
• Review concluded Oct 27, per reginfo.gov
• Result: "Consistent with Change," meaning the draft was edited during review
• Met with reviewers: AAPM, Hims & Hers, Alliance for Pharmacy Compounding, CSPI
How we got here:
• 2023: FDA restricted BPC-157 and other peptides over safety concerns
• July 2026: FDA advisers backed 6 of 7 peptides for compounding; FDA staff opposed all 7
• AP, citing two unnamed sources: the policy would temporarily allow some, including BPC-157
FDA can publish it any day.
Final text and peptide list: unknown.
Which peptides make the cut?
Peptide Base retweeted
🚨Update: the policy is out.
HHS says it won't take enforcement action against 503A pharmacies compounding 6 peptides while FDA works on a formal rule.
Allowed forms:
• BPC-157: injection, oral, topical
• TB-500: injection
• MOTS-c: injection
• Epitalon: injection, intermittent courses
• Semax: nasal
• KPV: oral, topical
Conditions:
• Patient-specific prescription
• Ingredients from FDA-registered makers, with lab certificates
• Single ingredient only
• Serious side effects reported to FDA
Still not FDA-approved. HHS says it can revisit if safety issues arise.
Formally publishes Oct 30. Public comments are open for 2 weeks.
Which peptide gets added next?
🚨FDA's peptide compounding policy has cleared White House review.
• Sent to OIRA Oct 14
• Review concluded Oct 27, per reginfo.gov
• Result: "Consistent with Change," meaning the draft was edited during review
• Met with reviewers: AAPM, Hims & Hers, Alliance for Pharmacy Compounding, CSPI
How we got here:
• 2023: FDA restricted BPC-157 and other peptides over safety concerns
• July 2026: FDA advisers backed 6 of 7 peptides for compounding; FDA staff opposed all 7
• AP, citing two unnamed sources: the policy would temporarily allow some, including BPC-157
FDA can publish it any day.
Final text and peptide list: unknown.
Which peptides make the cut?
🚨The peptide rush has already started.
TIME reports telehealth sites began marketing all six peptides shortly after HHS's notice:
$199–$249 a month
The policy doesn't formally publish until Oct 30.
Would you pay that?
🚨FDA's peptide compounding policy has cleared White House review.
• Sent to OIRA Oct 14
• Review concluded Oct 27, per reginfo.gov
• Result: "Consistent with Change," meaning the draft was edited during review
• Met with reviewers: AAPM, Hims & Hers, Alliance for Pharmacy Compounding, CSPI
How we got here:
• 2023: FDA restricted BPC-157 and other peptides over safety concerns
• July 2026: FDA advisers backed 6 of 7 peptides for compounding; FDA staff opposed all 7
• AP, citing two unnamed sources: the policy would temporarily allow some, including BPC-157
FDA can publish it any day.
Final text and peptide list: unknown.
Which peptides make the cut?
Not so fast.
The Alliance for Pharmacy Compounding says HHS's peptide policy "doesn't necessarily mean pharmacies can begin dispensing these peptides immediately."
Suppliers first have to prove their ingredients pass the policy's testing rules.
How long will that take?
Retatrutide just beat Ozempic head-to-head.
Lilly's Phase 3 TRANSCEND-T2D-2:
1,298 adults with type 2 diabetes, 80 weeks, vs Ozempic's top 2 mg dose.
• Weight: -20.9% vs -9.4%
• A1C: -2.2% vs -1.8%
• Quit over side effects: 7.9% vs 2.7%
• Skin-sensation side effect (dysesthesia): 6.5% vs 2.7%
What's next:
• TRIUMPH-5 vs tirzepatide: results est. Nov 2026
• FDA filing planned Q1 2027
Topline company data, not yet peer-reviewed.
Retatrutide is not approved anywhere.
Can tirzepatide hold its ground?
🚨RFK Jr. on Fox News:
"Virtually all peptides are illegal"
He says Americans still buy $1.5B-$3B a year, mainly from Chinese firms, with no FDA inspection.
His stated goal: a regulated market.
FDA's interim peptide policy is still under White House review 👀
89 shipments. $280K+.
That's unapproved GLP-1 and peptide product CBP officers in Cincinnati say they recently intercepted (per CBP Chicago).
It comes as FDA's interim peptide compounding access policy awaits White House review.
Crackdown and access push at once?
Protecting public health and safety at the border! 🛑📦
Across 89 separate shipments, CBP officers in Cincinnati recently intercepted a massive wave of smuggled, unapproved GLP-1 and peptide products, totaling $280,106.20 in illicit pharmaceuticals.
Why do we stop this? Unregulated, unverified peptides and weight-loss drugs entering the country bypass critical FDA oversight, sterility checks, and quality controls. Buyers have zero guarantee of what is actually inside these unapproved vials—risking contamination, incorrect dosages, severe side effects, and dangerous health consequences.
Keeping unapproved, potentially toxic drugs out of our communities is a vital part of our mission to safeguard American consumers. 💪🔒
(Note: The photo shown depicts just one of the 89 intercepted seizures.)
#CBP #PublicHealth #ConsumerSafety #BorderSecurity #GLP1 #Peptides #PharmaceuticalSafety
From 5 a month to 217+.
That's ER visits referencing unapproved peptides in NSW, Australia, July 2025 vs Sept 2026 (NSW Health report, via SMH).
1,180 total. Some liver injuries needed transplant-service care.
Officials say the count is conservative 👀
